ANAPTYSBIO, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ANAPTYSBIO, INC. (ANAB) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$127.00 thousand for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-09-21
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$5.00K.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$122.00K.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $53.00K, a 95.49% decline year-over-year.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$167.00K, a 179.90% decline year-over-year.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$329.00K, a 129.85% decline from fiscal 2024.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $1.10M, a 75.23% decline from fiscal 2023.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $4.45M.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$4.82M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$127.00K 10-KT · filed 2026-09-21 | ||
| 2026-03-31 | -$122.00K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$329.00K 10-KT · filed 2026-09-21 | |||
| 2025-09-30 | $53.00K 10-Q · filed 2025-11-04 | -$114.00K derived: sum of 2 quarters · filed 2025-11-04 | -$258.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-06-30 | -$167.00K 10-Q · filed 2025-11-04 | -$311.00K derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-03-31 | -$144.00K 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $1.10M 10-KT · filed 2026-09-21 | |||
| 2024-09-30 | $1.17M 10-Q · filed 2025-11-04 | $1.38M derived: sum of 2 quarters · filed 2025-11-04 | $1.56M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $209.00K 10-Q · filed 2025-11-04 | $382.00K derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $173.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $4.45M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $1.26M 10-Q · filed 2024-11-05 | $917.00K derived: sum of 2 quarters · filed 2024-11-05 | $2.90M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | -$344.00K 10-Q · filed 2024-11-05 | $1.64M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $1.98M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | -$4.82M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | -$418.00K 10-K · filed 2024-03-11 | |||
| 2020-12-31 | -$342.00K 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $561.00K 10-K · filed 2022-03-07 | |||
| 2018-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $454.00K derived: sum of 2 quarters · filed 2021-02-25 | $578.00K derived: sum of 3 quarters · filed 2021-02-25 | $203.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $136.00K 10-Q · filed 2018-11-08 | $260.00K derived: sum of 2 quarters · filed 2018-11-08 | -$115.00K 10-Q · filed 2018-11-08 | -$924.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $124.00K 10-Q · filed 2018-08-07 | -$250.00K 10-Q · filed 2018-08-07 | -$1.06M derived: sum of 3 quarters · filed 2020-03-02 | -$1.04M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$801.00K 10-Q · filed 2018-05-08 | -$1.18M derived: sum of 2 quarters · filed 2020-03-02 | -$1.17M derived: sum of 3 quarters · filed 2020-03-02 | -$1.21M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$367.00K derived: sum of 2 quarters · filed 2020-03-02 | -$413.00K derived: sum of 3 quarters · filed 2020-03-02 | -$426.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $16.00K 10-Q · filed 2018-11-08 | -$30.00K derived: sum of 2 quarters · filed 2018-11-08 | -$43.00K 10-Q · filed 2018-11-08 | -$43.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$46.00K 10-Q · filed 2018-08-07 | -$59.00K 10-Q · filed 2018-08-07 | -$59.00K derived: sum of 3 quarters · filed 2019-02-28 | -$59.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$13.00K 10-Q · filed 2018-05-08 | -$13.00K derived: sum of 2 quarters · filed 2019-02-28 | -$13.00K derived: sum of 3 quarters · filed 2019-02-28 | -$13.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-10 | $0.00 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |